These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10619191)

  • 1. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 7. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
    Jorga K; Fotteler B; Banken L; Snell P; Steimer JL
    Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats.
    Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
    J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolcapone increases maximum concentration of levodopa.
    Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
    J Neural Transm (Vienna); 2000; 107(1):113-9. PubMed ID: 10809409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM; Nicholl DJ
    Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
    Thiffault C; Langston JW; Di Monte DA
    Exp Neurol; 2003 Sep; 183(1):173-9. PubMed ID: 12957500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.